FluGen, Inc.

Transforming vaccine efficacy in respiratory disease

[FluGen, Inc. @FluGenInc]

FluGen's M2SR in Lancet ID today showing superior resposne when combined with Fluzone High Dose in older adults versus Fluzone High Dose alone (https://t.co/3tk1IPfzsR) This could be a big improvement in preventing flu... https://t.co/f8nz4mQOdJ

[FluGen, Inc. @FluGenInc]

And while you're at it- take a look at Healthcare Business Today to read more about M2SR's potential
https://t.co/lJxjywgBQK

[FluGen, Inc. @FluGenInc]

Check us out in Drug Discovery & Development!

https://t.co/C2uvEj2Fh5

[FluGen, Inc. @FluGenInc]

On the latest episode of the @BioBossPodcast, FluGen Founder and CEO Paul Radspinner discusses his career journey and the science behind FluGen’s vaccine program. To hear the full podcast, head to the BioBoss website: https://t.co/fCMMA8Mp94

[FluGen, Inc. @FluGenInc]

We're excited to announce completion of first cohort in age de-escalation clinical trial of M2SR flu vaccine candidate in pediatric subjects ages 6 Months to 17 Years! https://t.co/eCbJqXdYMk

[FluGen, Inc. @FluGenInc]

More confirmation that mucosal immunity is critical https://t.co/jQZuJRApM9

[WARF (Wisconsin Alumni Research Foundation) @WARF_News]

.@UWMadison investigators are eligible to apply for @DeptofDefense funding to catalyze innovative medical solutions for military applications and rapidly migrate those technologies out of the lab and into use. #WisconsinInnovates https://t.co/wkGOI8g950

[University Research Park @UWMadisonURP]

.@FluGenInc announced the dosing of its first subject, in an unprecedented study of older adults ages 65-85 years, to evaluate the effectiveness of its intranasal #flu #vaccine. https://t.co/sqHV1oqw7Z #clinicaltrials

[FluGen, Inc. @FluGenInc]

We are pleased to announce the first subject has been dosed in phase 1b clinical trial of our intranasal M2SR Flu Vaccine, co-administered with High Dose Vaccine, in older adults!
See https://t.co/eCbJqXewBS for full announcement

[Andrew Lloyd ALA @ALA_Group]

[ALA Client News] #Naobios delivers @flugeninc’s M2SR #influenza #vaccine candidate for upcoming clinical trials

@FluSpinner

https://t.co/UOzfM722dS

[FluGen, Inc. @FluGenInc]

FluGen to Present at 40th Annual J.P. Morgan Healthcare Conference 1/12/22 @ 4:30 PM E.T.
Visit https://t.co/1jgQSTMzu6 for more info!

[FluGen, Inc. @FluGenInc]

FluGen management will be presenting at Baird's 2021 Global Healthcare Conference tonight @ 5:30 PM ET watch it here: https://t.co/CXMc2kbYfA

[FluGen, Inc. @FluGenInc]

Journal of Infectious Diseases publishes positive data from our Ph.2 human challenge study of our M2SR #flu #vaccine candidate, showing protection against highly drifted strain of H3N2 flu [https://t.co/7JvOcREpAc]

[FluGen, Inc. @FluGenInc]

We are happy to announce that @DeptofDefense has awarded us funding to conduct a safety & immunogenicity study to asses our M2SR #flu #vaccine candidate and the current standard of care high dose vaccine in adults 65 and older https://t.co/Ni2iIKMUoA

[FluGen, Inc. @FluGenInc]

Watch FluGen President & CEO Paul Radspinner speak at the @Jefferies 2021 Virtual Healthcare Conference
https://t.co/MOPkasulFM

[FluGen, Inc. @FluGenInc]

We are pleased to launch the first #flu #vaccine study of M2SR in adults up to 85. Funded by @NIH, our study will assess safety, tolerability, and immunological response in people vulnerable to flu. https://t.co/puQm7eWejM

[Aaron @aaronolver]

How @UWMadisonURP started How it's going

[Katherine Davis @katmdavis]

ICYMI, watch my interview with @FluGenInc CEO Paul Radspinner. We chatted about FluGen’s approach to developing a Covid-19 vaccine, what the biggest challenges are, and what vaccine-makers need to do to ensure patients they are safe and effective. https://t.co/69ZOTtwDdj

[FluGen, Inc. @FluGenInc]

Reminder: you can still register for tomorrow's virtual fireside chat to hear from our CEO Paul Radspinner

[Katherine Davis @katmdavis]

Mark your calendars! I'll be hosting a fireside chat with @FluGenInc CEO Paul Radpsinner on Sept. 29 to discuss the company's progress on developing a Covid-19 vaccine. FluGen was named one of @WisconsinInno's #CrisisInnovators last month. Register here: https://t.co/6cty7oDzt2

[American / European Biomanufacturing Summit @Generis_BIO]

In this episode of #ExecutiveCorner, we'll be taking a closer look with Andy Skibo from @FluGenInc & @RfwrightLSL from Life Science Leader at what factors are important for #risk mitigation and #leadership in the #biomanufacturing industry.

Listen now ➡️ https://t.co/RwVeJeOB6Q